Repurposing public sarcoma multi-omics for neoantigen discovery
Cancer Immunology, Immunotherapy · 21.04.2026 · 75 (5)
DOI: 10.1007/s00262-026-04395-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 21.04.2026. Verfasst von Panagiotis Mantas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Technology, Technical University of Denmark, 2800, Kongens Lyngby, Denmark. panman@dtu.dk. Hauptthemen laut MEDLINE: Sarcoma, Antigens, Neoplasm, Biomarkers, Tumor. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technical University of Denmark.
Abstract (Originalsprache)
Background
Soft tissue sarcomas, particularly complex karyotype sarcomas (CKS), are characterized as “immunologically cold” malignancies driven by structural instability rather than a high tumor mutational burden (TMB). Public “legacy” cohorts are a useful resource to uncover immunotherapy biomarkers. This study used the whole-exome sequencing (WES) and RNA-sequencing of CKS patients, to overcome technical limitations and to identify and prioritize neoantigens.
Methods
The systematic immunogenomic reanalysis was performed on a landmark cohort of CKS patients (Kim et al., 2018) with a custom bioinformatics workflow which was developed to uncover interpretable immunogenomic signals. This approach consisted of: (1) defining a quality-controlled “callable territory” and normalizing TMB metrics, respectively; (2) utilizing RNA-seq not only for expression filtering but as an orthogonal validation check for variant transcription and to distinguish functional amplifications from technical depth artifacts; and (3) applying a multi-modal epitope prediction pipeline to identify and prioritize high-affinity neoantigens derived from both somatic SNVs, indels and expressed gene fusions.
Results
The reanalysis shows that standard genome-wide metrics frequently underestimated the immunogenic potential. Normalizing the TMB refined quantitative mutation burden estimates and improved interpretation of low-coverage samples without essentially changing the overall cohort classification. Furthermore, integration of transcriptomic data facilitated the recovery of actionable targets in “low-TMB” tumors. A subset of fusion-derived peptides demonstrated predicted binding affinities competitive with SNV-derived candidates.
Conclusion
This study illustrates that technically constrained multi-omic datasets can be systematically re-analyzed to identify potential therapeutic targets. These data argue for looking beyond aggregate biomarkers; patient-specific, expressed neoepitopes may exist even in sarcomas typically described as immunologically “cold”.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Technology, Technical University of Denmark, 2800, Kongens Lyngby, Denmark. panman@dtu.dk.
- Department of Science and Environment, Roskilde University, 4000, Roskilde, Denmark.
Förderung
- Technical University of Denmark
Zitieren
APA
Mantas, P., & Krogfelt, K. A. (2026). Repurposing public sarcoma multi-omics for neoantigen discovery. Cancer Immunology, Immunotherapy, 75(5). https://doi.org/10.1007/s00262-026-04395-y
Vancouver
Mantas P, Krogfelt KA. Repurposing public sarcoma multi-omics for neoantigen discovery. Cancer Immunology, Immunotherapy. 2026;75(5). doi:10.1007/s00262-026-04395-y
BibTeX
@article{Mantas2026,
author = {Mantas, Panagiotis and Krogfelt, Karen A},
title = {Repurposing public sarcoma multi-omics for neoantigen discovery},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
volume = {75},
number = {5},
doi = {10.1007/s00262-026-04395-y}
}
EUVIMED